NRx Pharmaceuticals reports Q2 EPS (12c), consensus (14c)

As of June 30 we had $15.0M in cash and cash equivalents. These working capital assets are expected to fund the Company’s operations through the Q4, which is when data is expected from the ongoing Phase 2b/3 trial.The company is also evaluating operational efficiencies to extend this runway. “We anticipate multiple near-term data catalysts in our suicidal bipolar depression and chronic pain clinical programs. Our internal focus has been on driving our ongoing phase 2b/3 trial to a data readout, which we expect in Q4 2023. The newly-published peer-reviewed results from our phase 2 STABIL-B trial document that NRX-101 is the first oral antidepressant to demonstrate a statistically significant reduction in suicidality together with a statistically-significant reduction in depression compared to standard of care medication. Today, we have posted blinded results from our ongoing clinical trial documenting the 94% concordance in measurement of the primary endpoint between our study sites and our internal master raters. Psychiatry trials often succeed or fail based on their ability to control the accuracy with which the endpoints are measured and this measure of Inter-rater reliability exceeds that reported in the published literature.” said Stephen Willard, CEO and Director of NRx Pharmaceuticals